Pub Date : 2025-06-01DOI: 10.1016/j.cpccr.2025.100353
Ellen Zhang, Nam Q. Bui
{"title":"From the immunotherapy case files","authors":"Ellen Zhang, Nam Q. Bui","doi":"10.1016/j.cpccr.2025.100353","DOIUrl":"10.1016/j.cpccr.2025.100353","url":null,"abstract":"","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100353"},"PeriodicalIF":0.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144280168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Acute myeloid leukemia (AML) with the RUNX1::RUNX1T1 fusion is typically associated with a favorable prognosis. However, when it occurs alongside systemic mastocytosis (SM), the outcome is usually adverse. This report describes a case involving a 41-year-old male diagnosed with AML harboring the RUNX1::RUNX1T1 fusion, who was initially misdiagnosed due to the lack of a thorough bone marrow examination. Although molecular testing confirmed the RUNX1::RUNX1T1 fusion, the associated mast cell component was overlooked, as the initial evaluation focused on peripheral blood. Follow-up bone marrow aspiration revealed an increased population of spindle-shaped mast cells, leading to a revised diagnosis of systemic mastocytosis with associated hematological neoplasm (SM-AHN) upon detection of a C-KIT D816Y mutation. This case emphasizes the necessity for comprehensive diagnostic evaluations, including bone marrow analysis and molecular testing for KIT mutations, to accurately identify concurrent neoplasms. While AML with RUNX1::RUNX1T1 fusion generally has a favorable prognosis, the presence of systemic mastocytosis and KIT mutations complicate the clinical landscape, requiring careful monitoring and potential modification of therapeutic strategies.
{"title":"Post-induction bone marrow uncovers mastocytosis in a case of acute myeloid leukemia-Case report","authors":"Tharageswari Srinivasan , Siddarthan Manimuthu , Manu Jamwal , Nabhajit Mallik , Sreejesh Sreedharanunni , Narender Kumar , Prashant Sharma , Shano Naseem , Pankaj Malhotra , Man Updesh Singh Sachdeva","doi":"10.1016/j.cpccr.2025.100373","DOIUrl":"10.1016/j.cpccr.2025.100373","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) with the <em>RUNX1::RUNX1T1</em> fusion is typically associated with a favorable prognosis. However, when it occurs alongside systemic mastocytosis (SM), the outcome is usually adverse. This report describes a case involving a 41-year-old male diagnosed with AML harboring the <em>RUNX1::RUNX1T1</em> fusion, who was initially misdiagnosed due to the lack of a thorough bone marrow examination. Although molecular testing confirmed the <em>RUNX1::RUNX1T1</em> fusion, the associated mast cell component was overlooked, as the initial evaluation focused on peripheral blood. Follow-up bone marrow aspiration revealed an increased population of spindle-shaped mast cells, leading to a revised diagnosis of systemic mastocytosis with associated hematological neoplasm (SM-AHN) upon detection of a <em>C-KIT</em> D816Y mutation. This case emphasizes the necessity for comprehensive diagnostic evaluations, including bone marrow analysis and molecular testing for <em>KIT</em> mutations, to accurately identify concurrent neoplasms. While AML with <em>RUNX1::RUNX1T1 fusion</em> generally has a favorable prognosis, the presence of systemic mastocytosis and <em>KIT</em> mutations complicate the clinical landscape, requiring careful monitoring and potential modification of therapeutic strategies.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100373"},"PeriodicalIF":0.2,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144168093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-20DOI: 10.1016/j.cpccr.2025.100374
Laura Gutiérrez-Sainz , Rocío Rosas-Alonso , Carlos Rodríguez-Antolín , Carmen Rodríguez-Jiménez , Isabel Esteban Rodríguez , Rafael Peláez , Oliver Higuera Gómez , Julia Villamayor , Patricia Cruz-Castellanos , Alberto Peláez-García , Inmaculada Ibáñez de Cáceres , Javier de Castro Carpeño
Non-small-cell lung cancer (NSCLC) exemplifies how biomarker-driven therapies can alter the natural course of a disease. Clinically significant mutations in the epidermal growth factor receptor (EGFR) in NSCLC include a spectrum of substitutions, deletions, and insertions, mainly affecting exons 18 to 21. The most common EGFR mutations involve exon 19 deletions (19del) or the exon 21 L858R substitution, which are typically sensitive to tyrosine kinase inhibitors (TKIs) such as osimertinib. However, 10 % to 20 % of patients harbor uncommon EGFR mutations, which exhibit variable responses to TKIs. Notably, some rare exon 19 mutations are often undetectable by conventional polymerase chain reaction (PCR) assays. In this case report, we describe an NSCLC patient with a novel exon 19 EGFR mutation identified by next-generation sequencing (NGS), which was not detected by commercial PCR assays. The patient experienced a modest response to osimertinib. We also provide a review of the current literature regarding these uncommon EGFR mutations.
{"title":"A Novel Exon 19 EGFR mutation in a patient with lung adenocarcinoma: A Case Report and Literature Review","authors":"Laura Gutiérrez-Sainz , Rocío Rosas-Alonso , Carlos Rodríguez-Antolín , Carmen Rodríguez-Jiménez , Isabel Esteban Rodríguez , Rafael Peláez , Oliver Higuera Gómez , Julia Villamayor , Patricia Cruz-Castellanos , Alberto Peláez-García , Inmaculada Ibáñez de Cáceres , Javier de Castro Carpeño","doi":"10.1016/j.cpccr.2025.100374","DOIUrl":"10.1016/j.cpccr.2025.100374","url":null,"abstract":"<div><div>Non-small-cell lung cancer (NSCLC) exemplifies how biomarker-driven therapies can alter the natural course of a disease. Clinically significant mutations in the <em>epidermal growth factor receptor (EGFR)</em> in NSCLC include a spectrum of substitutions, deletions, and insertions, mainly affecting exons 18 to 21. The most common <em>EGFR</em> mutations involve exon 19 deletions (19del) or the exon 21 L858R substitution, which are typically sensitive to tyrosine kinase inhibitors (TKIs) such as osimertinib. However, 10 % to 20 % of patients harbor uncommon <em>EGFR</em> mutations, which exhibit variable responses to TKIs. Notably, some rare exon 19 mutations are often undetectable by conventional polymerase chain reaction (PCR) assays. In this case report, we describe an NSCLC patient with a novel exon 19 <em>EGFR</em> mutation identified by next-generation sequencing (NGS), which was not detected by commercial PCR assays. The patient experienced a modest response to osimertinib. We also provide a review of the current literature regarding these uncommon <em>EGFR</em> mutations.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100374"},"PeriodicalIF":0.2,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144168092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-10DOI: 10.1016/j.cpccr.2025.100370
Marie Semmler , Isabel Brinkmann , Can Aydogdu , Nikolaos Pyrgidis , Marc Kidess , Benedikt Ebner , Stephan Ledderose , Christian G. Stief , Julian Marcon , Maria Apfelbeck , Michael Chaloupka
We present the case of a 66-year-old patient with a biochemical recurrence of prostate cancer manifesting as an asymptomatic testicular metastasis. Two years after radical prostatectomy and salvage radiation, the prostate-specific antigen (PSA) level rose to 1.07ng/ml. PSMA PET/CT scan showed tracer accumulation in the left testicle. Inguinal orchiectomy confirmed the metastasis. After being non-detectable, the PSA level increased five months after orchiectomy, with PSMA PET/CT revealing positive iliac lymph nodes. In summary, the presented case illustrates orchiectomy as a metastasectomy. However, apart from a transient decrease in PSA, no medium-term oncological advantage could be seen.
{"title":"Resection of a singular metachronous testicular metastasis of prostate cancer: A case report","authors":"Marie Semmler , Isabel Brinkmann , Can Aydogdu , Nikolaos Pyrgidis , Marc Kidess , Benedikt Ebner , Stephan Ledderose , Christian G. Stief , Julian Marcon , Maria Apfelbeck , Michael Chaloupka","doi":"10.1016/j.cpccr.2025.100370","DOIUrl":"10.1016/j.cpccr.2025.100370","url":null,"abstract":"<div><div>We present the case of a 66-year-old patient with a biochemical recurrence of prostate cancer manifesting as an asymptomatic testicular metastasis. Two years after radical prostatectomy and salvage radiation, the prostate-specific antigen (PSA) level rose to 1.07ng/ml. PSMA PET/CT scan showed tracer accumulation in the left testicle. Inguinal orchiectomy confirmed the metastasis. After being non-detectable, the PSA level increased five months after orchiectomy, with PSMA PET/CT revealing positive iliac lymph nodes. In summary, the presented case illustrates orchiectomy as a metastasectomy. However, apart from a transient decrease in PSA, no medium-term oncological advantage could be seen.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100370"},"PeriodicalIF":0.2,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143927656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To date, no reported case of meningioma metastatic to the supraclavicular lymph node with concomitant CD5+ B-cell Lymphoma has been reported in the English literature. We report a modern case of 88-year-old man with recurrent anaplastic meningioma commenced on bevacizumab after failing multiple surgical resections and radiation therapy, found to have tumor dissemination to an ipsilateral supraclavicular lymph node with a unique coexistence of CD5+ B-cell Lymphoma. His disease’s key features of multiple recurrence of meningioma, surgical excisions and radiation therapy, failure on bevacizumab therapy and unique coexistence with lymphoma, are highlighted in concordance with the literature.
{"title":"Anaplastic meningioma to supraclavicular lymph node with malignant B cell lymphoma: A rare case report","authors":"Shrinjay Vyas , Clarissa Henson , Michelle Cholankeril , Heidi Fish","doi":"10.1016/j.cpccr.2025.100369","DOIUrl":"10.1016/j.cpccr.2025.100369","url":null,"abstract":"<div><div>To date, no reported case of meningioma metastatic to the supraclavicular lymph node with concomitant CD5+ <em>B</em>-cell Lymphoma has been reported in the English literature. We report a modern case of 88-year-old man with recurrent anaplastic meningioma commenced on bevacizumab after failing multiple surgical resections and radiation therapy, found to have tumor dissemination to an ipsilateral supraclavicular lymph node with a unique coexistence of CD5+ <em>B</em>-cell Lymphoma. His disease’s key features of multiple recurrence of meningioma, surgical excisions and radiation therapy, failure on bevacizumab therapy and unique coexistence with lymphoma, are highlighted in concordance with the literature.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100369"},"PeriodicalIF":0.2,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Although abemaciclib is an essential therapy for breast cancer, approximately 80 % of patients develop diarrhea. Abemaciclib undergoes excretion by the P-glycoprotein encoded by ATP-binding cassette subfamily B member 1 (ABCB1) in the small intestine during absorption. The polymorphism of this gene is associated with adverse effects such as pancytopenia. Therefore, we report a case of refractory diarrhea in which ABCB1 polymorphisms were investigated. A Japanese 44-year-old female was diagnosed with breast cancer (estrogen receptor positive, progesterone receptor positive, and human epidermal growth factor receptor 2-negative) accompanied with bone metastasis. Although the patient was initially treated with abemaciclib, letrozole (Femara), and leuprorelin, refractory diarrhea induced by abemaciclib occurred after six days of treatment. Serum abemaciclib concentrations were measured before and after the diarrhea alleviation and the ABCB1 (3435C>T, 1236T>C, and 2677G>T/A) polymorphisms involved in delayed abemaciclib excretion were examined. ABCB1 3435C>T polymorphism was also identified. The abemaciclib concentration prior to diarrhea alleviation was higher than the mean concentration in a large-scale clinical trial (current study; 326.7 ng/mL vs a large-scale clinical trial; 169–243 ng/mL). The patient discontinued abemaciclib as it was difficult for her to continue the dose (150 mg twice daily) because of the associated diarrhea, which was alleviated thereafter. The abemaciclib concentration after diarrhea alleviation was below the detection limit of 25.0 ng/mL. ABCB1 3435C>T polymorphism may be involved in the induction of refractory diarrhea by abemaciclib and may be an objective indicator for managing abemaciclib dosage.
{"title":"Refractory diarrhea in a patient with metastatic breast cancer with ABCB1 polymorphism: A case report","authors":"Moeko Iida , Yoshihiko Tasaki , Akiko Kato , Tomoya Yasujima , Hiroaki Yuasa , Yasuhiro Maeda , Yoshihisa Mimura , Kunihiro Odagiri , Yuka Kimura , Nanami Ito , Yasuhiro Horita , Yosuke Sugiyama , Yuji Hotta , Tatsuya Toyama , Yoko Furukawa-Hibi","doi":"10.1016/j.cpccr.2025.100367","DOIUrl":"10.1016/j.cpccr.2025.100367","url":null,"abstract":"<div><div>Although abemaciclib is an essential therapy for breast cancer, approximately 80 % of patients develop diarrhea. Abemaciclib undergoes excretion by the P-glycoprotein encoded by ATP-binding cassette subfamily B member 1 (<em>ABCB1</em>) in the small intestine during absorption. The polymorphism of this gene is associated with adverse effects such as pancytopenia. Therefore, we report a case of refractory diarrhea in which <em>ABCB1</em> polymorphisms were investigated. A Japanese 44-year-old female was diagnosed with breast cancer (estrogen receptor positive, progesterone receptor positive, and human epidermal growth factor receptor 2-negative) accompanied with bone metastasis. Although the patient was initially treated with abemaciclib, letrozole (Femara), and leuprorelin, refractory diarrhea induced by abemaciclib occurred after six days of treatment. Serum abemaciclib concentrations were measured before and after the diarrhea alleviation and the <em>ABCB1</em> (3435C><em>T</em>, 1236T><em>C</em>, and 2677G><em>T</em>/A) polymorphisms involved in delayed abemaciclib excretion were examined. <em>ABCB1</em> 3435C><em>T</em> polymorphism was also identified. The abemaciclib concentration prior to diarrhea alleviation was higher than the mean concentration in a large-scale clinical trial (current study; 326.7 ng/mL vs a large-scale clinical trial; 169–243 ng/mL). The patient discontinued abemaciclib as it was difficult for her to continue the dose (150 mg twice daily) because of the associated diarrhea, which was alleviated thereafter. The abemaciclib concentration after diarrhea alleviation was below the detection limit of 25.0 ng/mL. <em>ABCB1</em> 3435C><em>T</em> polymorphism may be involved in the induction of refractory diarrhea by abemaciclib and may be an objective indicator for managing abemaciclib dosage.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100367"},"PeriodicalIF":0.2,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143837932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast prostheses offer symmetry and femininity restoration for women post-mastectomy. They are fitted to an individual's bra size, but standard prostheses can be heavy and uncomfortable on the scar site. Custom-made breast prosthesis offers improved fit, contour matching, and reduced weight, which is beneficial to patients. We report a case of a specific patient with a large prosthesis who experienced significant comfort issues with her standard silicone prosthesis, and how a bespoke prosthesis was created from a scan of her residual contralateral breast and created using 3D printing such that it was lightweight.
Two 3D scans were taken, one of the patient's residual contralateral breast while wearing a comfortable and well-fitting bra, and the other of the mastectomy site. The scans were processed using STL file editing software Meshmixer and Nomad Sculpt, and the residual breast profile was isolated and mirrored across the centerline of the patient's body. This profile was then aligned with the mastectomy surgery site scan and combined to create the anterior side of the prosthesis. A Vat Polymerisation (VP) 3D printing technology was used to produce the breast prosthesis, which was 3D printed on a FormLabs 3B+ using the FormLabs Flexible 80A material.
The new 3d printed prosthesis design is lightweight and flexible and mirrors the existing breast to achieve anatomical symmetry. The bespoke prosthesis is 62 % lighter than the patient's previous silicone prosthesis. Additionally, the anterior of the prosthesis is a bespoke match of the mastectomy scar site, providing for a secure fit.
The patient has worn her custom-made breast prosthesis for over one year up to the time of writing, and continues to do so. She describes the prosthesis as comfortable, lightweight, and secure in her bra. The use of 3D printing presents an opportunity to enhance the quality of breast prosthesis according to individual patient preferences.
{"title":"3D printed lightweight breast prostheses for a patient of breast size 38F who was unhappy with the heavy weight of their silicone prosthesis","authors":"Lyons EmmaJude , Baban Chwanrow , Walsh Lorraine , O'Sullivan Kevin.J , O'Sullivan Aidan , Meany Siobhan , O'Sullivan Leonard W","doi":"10.1016/j.cpccr.2025.100366","DOIUrl":"10.1016/j.cpccr.2025.100366","url":null,"abstract":"<div><div>Breast prostheses offer symmetry and femininity restoration for women post-mastectomy. They are fitted to an individual's bra size, but standard prostheses can be heavy and uncomfortable on the scar site. Custom-made breast prosthesis offers improved fit, contour matching, and reduced weight, which is beneficial to patients. We report a case of a specific patient with a large prosthesis who experienced significant comfort issues with her standard silicone prosthesis, and how a bespoke prosthesis was created from a scan of her residual contralateral breast and created using 3D printing such that it was lightweight.</div><div>Two 3D scans were taken, one of the patient's residual contralateral breast while wearing a comfortable and well-fitting bra, and the other of the mastectomy site. The scans were processed using STL file editing software Meshmixer and Nomad Sculpt, and the residual breast profile was isolated and mirrored across the centerline of the patient's body. This profile was then aligned with the mastectomy surgery site scan and combined to create the anterior side of the prosthesis. A Vat Polymerisation (VP) 3D printing technology was used to produce the breast prosthesis, which was 3D printed on a FormLabs 3B+ using the FormLabs Flexible 80A material.</div><div>The new 3d printed prosthesis design is lightweight and flexible and mirrors the existing breast to achieve anatomical symmetry. The bespoke prosthesis is 62 % lighter than the patient's previous silicone prosthesis. Additionally, the anterior of the prosthesis is a bespoke match of the mastectomy scar site, providing for a secure fit.</div><div>The patient has worn her custom-made breast prosthesis for over one year up to the time of writing, and continues to do so. She describes the prosthesis as comfortable, lightweight, and secure in her bra. The use of 3D printing presents an opportunity to enhance the quality of breast prosthesis according to individual patient preferences.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100366"},"PeriodicalIF":0.2,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-01DOI: 10.1016/j.cpccr.2025.100365
Sijie Liu, Jing Wang
Background
Pulmonary lymphangitic carcinomatosis (PLC) is a rare secondary metastatic cancer. Cough and dyspnea are the common clinical manifestations of PLC. PLC is often confused with pulmonary sarcoidosis, pulmonary edema, pneumoconiosis, and interstitial pneumonia, which leads to delayed diagnosis and poor prognosis.
Case Presentation
A 23-year-old female with a cough. Gastric cancer was confirmed by gastroscopy. The abnormal changes in the lung were considered to be consistent with PLC.
Conclusion
PCL is often misdiagnosed or delayed. PLC should be considered when cough, dyspnea, and chest CT show thickening of the peribronchovascular and interlobular septa or when pleural effusion and enlargement of mediastinal lymph nodes.
{"title":"Pulmonary lymphangitic carcinomatosis secondary to gastric Cancer in a Young Woman: A case report","authors":"Sijie Liu, Jing Wang","doi":"10.1016/j.cpccr.2025.100365","DOIUrl":"10.1016/j.cpccr.2025.100365","url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary lymphangitic carcinomatosis (PLC) is a rare secondary metastatic cancer. Cough and dyspnea are the common clinical manifestations of PLC. PLC is often confused with pulmonary sarcoidosis, pulmonary edema, pneumoconiosis, and interstitial pneumonia, which leads to delayed diagnosis and poor prognosis.</div></div><div><h3>Case Presentation</h3><div>A 23-year-old female with a cough. Gastric cancer was confirmed by gastroscopy. The abnormal changes in the lung were considered to be consistent with PLC.</div></div><div><h3>Conclusion</h3><div>PCL is often misdiagnosed or delayed. PLC should be considered when cough, dyspnea, and chest CT show thickening of the peribronchovascular and interlobular septa or when pleural effusion and enlargement of mediastinal lymph nodes.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100365"},"PeriodicalIF":0.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143783214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-23DOI: 10.1016/j.cpccr.2025.100364
P. Meister , J. Rawitzer , M. Reschke , H.A. Baba , U. Neumann , M. Kaths
Low-grade appendiceal mucinous neoplasms (LAMNs) may lead to pseudomyxoma peritonei and require specialized surgical therapy. By pathological definition, these tumor entities exhibit neither invasive growth nor develop systemic or lymph node metastases. We report the case of a 43-year-old female presenting with a metachronous splenic metastasis of low-grade pseudomyxoma peritonei four years after surgical therapy. The patient was treated successfully via laparoscopic splenectomy. While the spleen itself is an extremely rare location for metastasizing colonic cancer, a LAMN metastasis in this location has not been previously described. A literature review of pseudomyxoma recurrence reveals that LAMNs might indeed recur in extraperitoneal locations, questioning their pathophysiological definition of non-metastasizing behavior.
{"title":"Intrasplenic metastasis of appendiceal low-grade mucinous neoplasm – A case report and review of the literature","authors":"P. Meister , J. Rawitzer , M. Reschke , H.A. Baba , U. Neumann , M. Kaths","doi":"10.1016/j.cpccr.2025.100364","DOIUrl":"10.1016/j.cpccr.2025.100364","url":null,"abstract":"<div><div>Low-grade appendiceal mucinous neoplasms (LAMNs) may lead to pseudomyxoma peritonei and require specialized surgical therapy. By pathological definition, these tumor entities exhibit neither invasive growth nor develop systemic or lymph node metastases. We report the case of a 43-year-old female presenting with a metachronous splenic metastasis of low-grade pseudomyxoma peritonei four years after surgical therapy. The patient was treated successfully via laparoscopic splenectomy. While the spleen itself is an extremely rare location for metastasizing colonic cancer, a LAMN metastasis in this location has not been previously described. A literature review of pseudomyxoma recurrence reveals that LAMNs might indeed recur in extraperitoneal locations, questioning their pathophysiological definition of non-metastasizing behavior.</div></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"18 ","pages":"Article 100364"},"PeriodicalIF":0.2,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号